OX40 Regulates Both Innate and Adaptive Immunity and Promotes Nonalcoholic Steatohepatitis

Guangyong Sun(Capital Medical University), Dong Zhang(Qingdao University), Chunpan Zhang(Beijing Friendship Hospital), Qianyi Wang(Capital Medical University), Shuxiang Li(Capital Medical University), Zhongtao Zhang(Capital Medical University), Wei Guo(University of Maryland, Baltimore), Xin‐Min Li(University of Alberta), Tianqi Wang(Wenzhou Medical University), Hua Meng(Capital Medical University), Dan Tian(Sun Yat-sen University), Hufeng Xu(Capital Medical University), Yue Tian(Capital Medical University), Dan Wei(Guangxi University), Hua Jin(Jinan Maternity And Care Hospital), Xiaojing Sun(Capital Medical University), Wen Shi(Capital Medical University), Xiaojuan Ou(Capital Medical University), Jidong Jia, Kai Liu(First People's Hospital of Yunnan Province), Xinyan Zhao(Capital Medical University)
Cell Reports
December 1, 2018
10.1016/j.celrep.2018.12.006
Cited by 58

Related Papers

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China
|Schizophrenia Research|2015|320
Supraspinal Brain-Derived Neurotrophic Factor Signaling: A Novel Mechanism for Descending Pain Facilitation
|Journal of Neuroscience|2006|186
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial
|The Lancet Oncology|2021|184